Exalpha Biologicals, Inc.

Latest News

Exalpha Biologicals, Inc. is now a US distributor for Nordic-Mubio products

Nordic-MUbio develops and manufactures high quality antibody reagents for use in R&D. All our products are manufactured according to strict ISO 9001 quality guidelines, and our focus is on developing antibodies targetting Cell Adhesion, Nuclear and Cytoskeletal Proteins.

Nordic-MUbio is one of the leading antibody companies developing antibodies for zebrafish research – we currently have over 50 antibodies validated for immunofluorescence in zebrafish.

Learn More

Latest References

Akazawa, Y., et al. "Endoplasmic Reticulum Stress Contributes to Helicobacter Pylori VacA-Induced Apoptosis" PLoS ONE 8(12): e82322

Learn More

Homa, N.J., et al. "Epstein-Barr Virus Induces Global Changes in Cellular mRNA Isoform Usage That Are Important for the Maintenance of Latency" J. Virol., 2013, 87, 12291-12301

Learn More
Exalpha Biologicals, Inc.

SHP-2 (224-529)/PTPN11

  • Product Code: X1663E
  • Size: 20 µg
  • Availability: In Stock In Stock
  • Price (USD): $361

Cat #

X1663E		 Quantity:      

Data Sheet

Product Name

SHP-2 (224-529)/PTPN11

Host/Source

E.coli

Product Type

Active Enzyme

Reactivity

Human

Applications

Enyzme activity assay standard

Size

20 µg

Price (USD)

$361

Background

SHP-2, also known as Tyrosine-protein phosphatase, non-receptor type 11 (PTPN11), Protein-tyrosine phosphatase 2C, PTP-2C, PTP-1D, SH-PTP3 and SH-PTP2 is protein tyrosine phosphatase which relays signals from growth factor receptors to Ras and other effectors. Germline PTPN11 mutations underlie ~50% of Noonan Syndrome (NS), a developmental disorder associated with an elevated risk of juvenile myelomonocytic leukemia (JMML). Somatic PTPN11 mutations were recently identified in ~35% of JMML patients; these mutations introduce amino acid substitutions that are distinct from those found in NS. These myeloid leukemias include activating mutations as in the RAS family members, and in the receptor tyrosine kinases KIT and FLT3, loss of function of NF-1 mutants, and gain-of-function mutations in the hematopoietic phosphatase SHP-2. Although these mutations collectively account for as many as 50% of cases of AML, with rare exception, only one of these is mutant in any given patient. This epidemiologic observation suggests that these mutations can be viewed as a complementation group and that any one of these is sufficient to contribute proliferative and survival advantage to a leukemic cell.

Immunogen

Recombinant enyzme produced in E. coli

Formulation

Provided in 25 mM Tris-HCl, 75 mM NaCl, pH 8.0, 0.05% Tween, 1 mM DTT and 50% glycerol 2 mM EDTA, 10 mM glutathione.

Customer Storage

Enzyme should be stored at -20°C. Enzyme should be kept on ice when dispensing

Target Molecular Weight

59.5 kDa

Database Links:

GenBankNM_002834Human

References

[1] Ahmad S., Banville D.L., Zhao Z., Fischer E.H., Shen S.H.;
A widely expressed human protein-tyrosine phosphatase containing src homology 2 domains.;
Proc. Natl. Acad. Sci. U.S.A. 90:2197-2201(1993).

[2] Vogel W., Lammers R., Huang J., Ullrich A.;
Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation.; Science 259:1611-1614(1993).

[3] Adachi M., Sekiya M., Miyachi T., Matsuno K., Hinoda Y., Imai K., Yachi A.;
Molecular cloning of a novel protein-tyrosine phosphatase SH-PTP3 with sequence similarity to the src-homology region 2.; FEBS Lett. 314:335-339(1992).

[4] Bastien L., Ramachandran C., Liu S., Adam M.;
Cloning, expression and mutational analysis of SH-PTP2, human protein-tyrosine phosphatase. Biochem. Biophys. Res. Commun. 196:124-133(1993).

[5] Freeman R.M. Jr., Plutzky J., Neel B.G.;
Identification of a human src homology 2-containing protein-tyrosine-phosphatase: a putative homolog of Drosophila corkscrew.; Proc. Natl. Acad. Sci. U.S.A. 89:11239-11243(1992).

[6] Bennett A.M., Tang T.L., Sugimoto S., Walsh C.T., Neel B.G.;
Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras. Proc. Natl. Acad. Sci. U.S.A. 91:7335-7339(1994).

[7] Salomon A.R., Ficarro S.B., Brill L.M., Brinker A., Phung Q.T., Ericson C., Sauer K., Brock A., Horn D.M., Schultz P.G., Peters E.C.;
Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry.; Proc. Natl. Acad. Sci. U.S.A. 100:443-448(2003).

[8] Kharitonenkov A., Chen Z., Sures I., Wang H., Schilling J., Ullrich A.;
A family of proteins that inhibit signalling through tyrosine kinase receptors.; Nature 386:181-186(1997).

[9] Hof P., Pluskey S., Dhe-Paganon S., Eck M.J., Shoelson S.E.;
Crystal structure of the tyrosine phosphatase SHP-2.; Cell 92:441-450(1998).

[10] Tartaglia M., Mehler E.L., Goldberg R., Zampino G., Brunner H.G., Kremer H., van der Burgt I., Crosby A.H., Ion A., Jeffery S., Kalidas K., Patton M.A., Kucherlapati R.S., Gelb B.D.;
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.; Nat. Genet. 29:465-468(2001).